Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy

Menopause. 2025 Jan 1;32(1):12-22. doi: 10.1097/GME.0000000000002481.

Abstract

Objective: To assess the association of systolic and diastolic blood pressure (SBP and DBP) in recently menopausal women with white matter hyperintensity (WMH) volume later in life and determine whether short-term menopausal hormone therapy (mHT) modifies these associations.

Methods: Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter, randomized, double-blinded, placebo-controlled 4-year mHT trial (oral conjugated equine estrogens or transdermal 17β-estradiol). KEEPS continuation was an observational follow-up of the participants 10 years after the end of mHT. The associations between KEEPS baseline blood pressure (BP) with KEEPS continuation WMH volume were examined adjusting for covariates in model 1 (age, total intracranial volume, study site, mHT type) and model 2 (additionally conventional CVD risk factors). Interaction terms (BP × mHT type) were added into the linear regression models.

Results: The mean ± SD ages of participants were 53 (±2) years at KEEPS baseline and 67 (±2) years at KEEPS continuation. Elevated BP at KEEPS baseline was associated with greater WMH volume measured 14 years later (model 1: SBP: β = 0.01 [95% CI, 0.001-0.01] and DBP: β = 0.01 [95% CI, 0.003-0.03]) and after additionally adjusting for CVD risk factors (model 2). We did not find any evidence that mHT versus placebo modified these associations. Topographically, higher BP was associated with greater periventricular WMH in the frontal and parietal lobes.

Conclusion: Our findings suggest the importance of maintaining normal BP in recently postmenopausal women with low CVD risk, irrespective of short-term mHT usage, to potentially reduce the risk of WMH later in life.

Trial registration: ClinicalTrials.gov NCT00154180.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Blood Pressure* / drug effects
  • Double-Blind Method
  • Estradiol / administration & dosage
  • Estrogen Replacement Therapy*
  • Estrogens, Conjugated (USP)* / administration & dosage
  • Estrogens, Conjugated (USP)* / adverse effects
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Menopause
  • Middle Aged
  • Postmenopause
  • White Matter* / diagnostic imaging
  • White Matter* / drug effects
  • White Matter* / pathology

Substances

  • Estrogens, Conjugated (USP)
  • Estradiol

Associated data

  • ClinicalTrials.gov/NCT00154180